The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Idiopathic Pulmonary Fibrosis-Global Market Insights and Sales Trends 2024
Synopsis
Idiopathic pulmonary fibrosis is a condition in which the tissues in the lungs become thick and stiff over time. As a result of thickening of lung tissues, brain and other organs are unable receive optimum oxygen.
The global Idiopathic Pulmonary Fibrosis market size is expected to reach US$ 3373.4 million by 2029, growing at a CAGR of 9.5% from 2023 to 2029. The market is mainly driven by the significant applications of Idiopathic Pulmonary Fibrosis in various end use industries. The expanding demands from the Hospitals, Clinics, Ambulatory Surgical Centers and Academic and Research Organizations, are propelling Idiopathic Pulmonary Fibrosis market. Systemic Corticosteroids, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Immunosuppressant Drugs segment is estimated at % CAGR for the next seven-year period.
An increase in the incidence and prevalence of fibrotic diseases is the primary driver for the growth of this market. Idiopathic pulmonary fibrosis most commonly affects middle-aged to older adults and is characterized by the scarring of lung tissues. In older people, these scars tend to build up and affect the normal functioning of lungs. Thus, an increase in aging population leads to increased prevalence of the disease, which in turn results in market growth during the predicted period.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Idiopathic Pulmonary Fibrosis, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Idiopathic Pulmonary Fibrosis market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Idiopathic Pulmonary Fibrosis market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Idiopathic Pulmonary Fibrosis sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Idiopathic Pulmonary Fibrosis covered in this report include MediciNova, Boehringer Ingelheim, F. Hoffmann-La Roche, FibroGen, Promedior, Merck, Galapagos, Prometic Life Sciences and Cipla, etc.
The global Idiopathic Pulmonary Fibrosis market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
MediciNova
Boehringer Ingelheim
F. Hoffmann-La Roche
FibroGen
Promedior
Merck
Galapagos
Prometic Life Sciences
Cipla
Global Idiopathic Pulmonary Fibrosis market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Idiopathic Pulmonary Fibrosis market, Segment by Type:
Systemic Corticosteroids
Immunosuppressant Drugs
Tyrosine Kinase Inhibitors
Antifibrotic Agents
Global Idiopathic Pulmonary Fibrosis market, by Application
Hospitals
Clinics
Ambulatory Surgical Centers
Academic and Research Organizations
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Idiopathic Pulmonary Fibrosis companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Idiopathic pulmonary fibrosis is a condition in which the tissues in the lungs become thick and stiff over time. As a result of thickening of lung tissues, brain and other organs are unable receive optimum oxygen.
The global Idiopathic Pulmonary Fibrosis market size is expected to reach US$ 3373.4 million by 2029, growing at a CAGR of 9.5% from 2023 to 2029. The market is mainly driven by the significant applications of Idiopathic Pulmonary Fibrosis in various end use industries. The expanding demands from the Hospitals, Clinics, Ambulatory Surgical Centers and Academic and Research Organizations, are propelling Idiopathic Pulmonary Fibrosis market. Systemic Corticosteroids, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Immunosuppressant Drugs segment is estimated at % CAGR for the next seven-year period.
An increase in the incidence and prevalence of fibrotic diseases is the primary driver for the growth of this market. Idiopathic pulmonary fibrosis most commonly affects middle-aged to older adults and is characterized by the scarring of lung tissues. In older people, these scars tend to build up and affect the normal functioning of lungs. Thus, an increase in aging population leads to increased prevalence of the disease, which in turn results in market growth during the predicted period.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Idiopathic Pulmonary Fibrosis, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Idiopathic Pulmonary Fibrosis market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Idiopathic Pulmonary Fibrosis market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Idiopathic Pulmonary Fibrosis sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Idiopathic Pulmonary Fibrosis covered in this report include MediciNova, Boehringer Ingelheim, F. Hoffmann-La Roche, FibroGen, Promedior, Merck, Galapagos, Prometic Life Sciences and Cipla, etc.
The global Idiopathic Pulmonary Fibrosis market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
MediciNova
Boehringer Ingelheim
F. Hoffmann-La Roche
FibroGen
Promedior
Merck
Galapagos
Prometic Life Sciences
Cipla
Global Idiopathic Pulmonary Fibrosis market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Idiopathic Pulmonary Fibrosis market, Segment by Type:
Systemic Corticosteroids
Immunosuppressant Drugs
Tyrosine Kinase Inhibitors
Antifibrotic Agents
Global Idiopathic Pulmonary Fibrosis market, by Application
Hospitals
Clinics
Ambulatory Surgical Centers
Academic and Research Organizations
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Idiopathic Pulmonary Fibrosis companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Idiopathic Pulmonary Fibrosis
1.1 Idiopathic Pulmonary Fibrosis Market Overview
1.1.1 Idiopathic Pulmonary Fibrosis Product Scope
1.1.2 Idiopathic Pulmonary Fibrosis Market Status and Outlook
1.2 Global Idiopathic Pulmonary Fibrosis Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Idiopathic Pulmonary Fibrosis Market Size by Region (2018-2029)
1.4 Global Idiopathic Pulmonary Fibrosis Historic Market Size by Region (2018-2023)
1.5 Global Idiopathic Pulmonary Fibrosis Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Idiopathic Pulmonary Fibrosis Market Size (2018-2029)
1.6.1 North America Idiopathic Pulmonary Fibrosis Market Size (2018-2029)
1.6.2 Europe Idiopathic Pulmonary Fibrosis Market Size (2018-2029)
1.6.3 Asia-Pacific Idiopathic Pulmonary Fibrosis Market Size (2018-2029)
1.6.4 Latin America Idiopathic Pulmonary Fibrosis Market Size (2018-2029)
1.6.5 Middle East & Africa Idiopathic Pulmonary Fibrosis Market Size (2018-2029)
2 Idiopathic Pulmonary Fibrosis Market by Type
2.1 Introduction
2.1.1 Systemic Corticosteroids
2.1.2 Immunosuppressant Drugs
2.1.3 Tyrosine Kinase Inhibitors
2.1.4 Antifibrotic Agents
2.2 Global Idiopathic Pulmonary Fibrosis Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Idiopathic Pulmonary Fibrosis Historic Market Size by Type (2018-2023)
2.2.2 Global Idiopathic Pulmonary Fibrosis Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Idiopathic Pulmonary Fibrosis Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Idiopathic Pulmonary Fibrosis Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Idiopathic Pulmonary Fibrosis Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Idiopathic Pulmonary Fibrosis Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Idiopathic Pulmonary Fibrosis Revenue Breakdown by Type (2018-2029)
3 Idiopathic Pulmonary Fibrosis Market Overview by Application
3.1 Introduction
3.1.1 Hospitals
3.1.2 Clinics
3.1.3 Ambulatory Surgical Centers
3.1.4 Academic and Research Organizations
3.2 Global Idiopathic Pulmonary Fibrosis Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Idiopathic Pulmonary Fibrosis Historic Market Size by Application (2018-2023)
3.2.2 Global Idiopathic Pulmonary Fibrosis Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Idiopathic Pulmonary Fibrosis Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Idiopathic Pulmonary Fibrosis Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Idiopathic Pulmonary Fibrosis Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Idiopathic Pulmonary Fibrosis Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Idiopathic Pulmonary Fibrosis Revenue Breakdown by Application (2018-2029)
4 Idiopathic Pulmonary Fibrosis Competition Analysis by Players
4.1 Global Idiopathic Pulmonary Fibrosis Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Idiopathic Pulmonary Fibrosis as of 2022)
4.3 Date of Key Players Enter into Idiopathic Pulmonary Fibrosis Market
4.4 Global Top Players Idiopathic Pulmonary Fibrosis Headquarters and Area Served
4.5 Key Players Idiopathic Pulmonary Fibrosis Product Solution and Service
4.6 Competitive Status
4.6.1 Idiopathic Pulmonary Fibrosis Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 MediciNova
5.1.1 MediciNova Profile
5.1.2 MediciNova Main Business
5.1.3 MediciNova Idiopathic Pulmonary Fibrosis Products, Services and Solutions
5.1.4 MediciNova Idiopathic Pulmonary Fibrosis Revenue (US$ Million) & (2018-2023)
5.1.5 MediciNova Recent Developments
5.2 Boehringer Ingelheim
5.2.1 Boehringer Ingelheim Profile
5.2.2 Boehringer Ingelheim Main Business
5.2.3 Boehringer Ingelheim Idiopathic Pulmonary Fibrosis Products, Services and Solutions
5.2.4 Boehringer Ingelheim Idiopathic Pulmonary Fibrosis Revenue (US$ Million) & (2018-2023)
5.2.5 Boehringer Ingelheim Recent Developments
5.3 F. Hoffmann-La Roche
5.3.1 F. Hoffmann-La Roche Profile
5.3.2 F. Hoffmann-La Roche Main Business
5.3.3 F. Hoffmann-La Roche Idiopathic Pulmonary Fibrosis Products, Services and Solutions
5.3.4 F. Hoffmann-La Roche Idiopathic Pulmonary Fibrosis Revenue (US$ Million) & (2018-2023)
5.3.5 FibroGen Recent Developments
5.4 FibroGen
5.4.1 FibroGen Profile
5.4.2 FibroGen Main Business
5.4.3 FibroGen Idiopathic Pulmonary Fibrosis Products, Services and Solutions
5.4.4 FibroGen Idiopathic Pulmonary Fibrosis Revenue (US$ Million) & (2018-2023)
5.4.5 FibroGen Recent Developments
5.5 Promedior
5.5.1 Promedior Profile
5.5.2 Promedior Main Business
5.5.3 Promedior Idiopathic Pulmonary Fibrosis Products, Services and Solutions
5.5.4 Promedior Idiopathic Pulmonary Fibrosis Revenue (US$ Million) & (2018-2023)
5.5.5 Promedior Recent Developments
5.6 Merck
5.6.1 Merck Profile
5.6.2 Merck Main Business
5.6.3 Merck Idiopathic Pulmonary Fibrosis Products, Services and Solutions
5.6.4 Merck Idiopathic Pulmonary Fibrosis Revenue (US$ Million) & (2018-2023)
5.6.5 Merck Recent Developments
5.7 Galapagos
5.7.1 Galapagos Profile
5.7.2 Galapagos Main Business
5.7.3 Galapagos Idiopathic Pulmonary Fibrosis Products, Services and Solutions
5.7.4 Galapagos Idiopathic Pulmonary Fibrosis Revenue (US$ Million) & (2018-2023)
5.7.5 Galapagos Recent Developments
5.8 Prometic Life Sciences
5.8.1 Prometic Life Sciences Profile
5.8.2 Prometic Life Sciences Main Business
5.8.3 Prometic Life Sciences Idiopathic Pulmonary Fibrosis Products, Services and Solutions
5.8.4 Prometic Life Sciences Idiopathic Pulmonary Fibrosis Revenue (US$ Million) & (2018-2023)
5.8.5 Prometic Life Sciences Recent Developments
5.9 Cipla
5.9.1 Cipla Profile
5.9.2 Cipla Main Business
5.9.3 Cipla Idiopathic Pulmonary Fibrosis Products, Services and Solutions
5.9.4 Cipla Idiopathic Pulmonary Fibrosis Revenue (US$ Million) & (2018-2023)
5.9.5 Cipla Recent Developments
6 North America
6.1 North America Idiopathic Pulmonary Fibrosis Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Idiopathic Pulmonary Fibrosis Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Idiopathic Pulmonary Fibrosis Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Idiopathic Pulmonary Fibrosis Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Idiopathic Pulmonary Fibrosis Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Idiopathic Pulmonary Fibrosis Market Dynamics
11.1 Idiopathic Pulmonary Fibrosis Industry Trends
11.2 Idiopathic Pulmonary Fibrosis Market Drivers
11.3 Idiopathic Pulmonary Fibrosis Market Challenges
11.4 Idiopathic Pulmonary Fibrosis Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
